有作用
发表于 2025-3-21 17:40:49
书目名称Guide to Targeted Therapies: Treatment Resistance in Lung Cancer影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0390911<br><br> <br><br>书目名称Guide to Targeted Therapies: Treatment Resistance in Lung Cancer影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0390911<br><br> <br><br>书目名称Guide to Targeted Therapies: Treatment Resistance in Lung Cancer网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0390911<br><br> <br><br>书目名称Guide to Targeted Therapies: Treatment Resistance in Lung Cancer网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0390911<br><br> <br><br>书目名称Guide to Targeted Therapies: Treatment Resistance in Lung Cancer被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0390911<br><br> <br><br>书目名称Guide to Targeted Therapies: Treatment Resistance in Lung Cancer被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0390911<br><br> <br><br>书目名称Guide to Targeted Therapies: Treatment Resistance in Lung Cancer年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0390911<br><br> <br><br>书目名称Guide to Targeted Therapies: Treatment Resistance in Lung Cancer年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0390911<br><br> <br><br>书目名称Guide to Targeted Therapies: Treatment Resistance in Lung Cancer读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0390911<br><br> <br><br>书目名称Guide to Targeted Therapies: Treatment Resistance in Lung Cancer读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0390911<br><br> <br><br>
同音
发表于 2025-3-21 23:46:00
https://doi.org/10.1007/978-3-8349-4015-5Systemic therapy for advanced non-small-cell lung cancer (NSCLC) depends upon tumor biology or tumor histology, with targeted agents preferentially used in individuals with a specific driver mutation and chemotherapy used for patients whose tumors do not harbor such mutations, or following failure of targeted therapy.
初学者
发表于 2025-3-22 02:23:57
http://reply.papertrans.cn/40/3910/390911/390911_3.png
CANDY
发表于 2025-3-22 04:57:18
Introduction,In 2015, once again, statistics confirm non-small-cell lung cancer (NSCLC) as the leading cause of cancer-related death worldwide (Figure 1.1), with a median survival that rarely exceeds 10–12 months in unselected patients with metastatic disease treated with conventional chemotherapy .
男生戴手铐
发表于 2025-3-22 11:46:23
http://reply.papertrans.cn/40/3910/390911/390911_5.png
通便
发表于 2025-3-22 13:37:32
http://reply.papertrans.cn/40/3910/390911/390911_6.png
通便
发表于 2025-3-22 17:15:36
http://reply.papertrans.cn/40/3910/390911/390911_7.png
洞察力
发表于 2025-3-23 00:25:18
https://doi.org/10.1007/978-3-030-99732-8s approval was based on the results of a large phase III study that showed improved overall survival with the combination of bevacizumab, a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF), plus carboplatin/paclitaxel chemotherapy versus chemotherapy alone .
enormous
发表于 2025-3-23 03:03:21
Resistance to crizotinib and therapeutic options,y to crizotinib due to the emergence of acquired resistance. In addition, approximately 30% of patients do not respond to the therapy even in the presence of the target, anaplastic lymphoma kinase (ALK).
Slit-Lamp
发表于 2025-3-23 08:36:17
Resistance to anti-angiogenic drugs and therapeutic options,s approval was based on the results of a large phase III study that showed improved overall survival with the combination of bevacizumab, a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor (VEGF), plus carboplatin/paclitaxel chemotherapy versus chemotherapy alone .